Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
|Videos|April 6, 2016
Rafat Abonour on the Importance of Raising Awareness About Myeloma
Author(s)Rafat Abonour
Rafat Abonour, MD, professor of Medicine, pathology, and laboratory medicine at Indiana University, discusses the importance of raising awareness about multiple myeloma and his Miles for Myeloma initiative.
Advertisement
Rafat Abonour, MD, professor of Medicine, pathology, and laboratory medicine at Indiana University, discusses the importance of raising awareness about multiple myeloma and his
Advertisement
Related to this article
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.
Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.
My multiple myeloma nurse case manager sat in on every appointment, helped me appeal an insurance denial and made sure I never felt like just a number.
Advertisement
Advertisement